Monitoring agency report for the Quarter ended 31.03.2025 for funds raised through Preferential issue.
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ind-Swift Laboratories submitted the quarterly Monitoring Agency Report from CARE Ratings for the quarter ended March 31, 2025, covering its Rs. 314.60 crore preferential issue of 2.60 crore fully convertible warrants allotted on August 30, 2024. Of the total, Rs. 91.11 crore has been utilized cumulatively, with Rs. 33.46 crore deployed in Q4FY25 alone, leaving only Rs. 1.19 crore unutilized (plus Rs. 0.33 crore interest on FDs). The company used Rs. 21.21 crore of the Rs. 75 crore General Corporate Purpose allocation to repay an overdraft facility, even though the offer document did not specifically list overdraft repayment as a GCP use. CARE flagged concerns that funds moved from the monitoring account into a Bank of India overdraft account and then into multiple current accounts with group-company transactions, making direct verification difficult; management says all use is documented and aligned with the offer document. Separately, CARE warned that the current share price of Rs. 70.19 is well below the warrant exercise price of Rs. 121, raising the risk that warrant subscribers may not convert, which could affect the viability of the issue objects.
Slow utilization (only ~29% of proceeds deployed in 7 months) and the monitoring agency's flagging of opaque fund routing through group accounts are negatives for transparency. The big overhang is the warrant conversion risk — with the stock trading ~42% below the exercise price, the company may not collect the bulk of the Rs. 314.60 crore, which could stall its expansion plans.